ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Andrew C. Phillips(AbbVie (United States)), Edward B. Reilly(AbbVie (United States)), Fritz G. Buchanan(AbbVie (United States)), Peter J. DeVries(AbbVie (United States)), Laura M. McKay(AbbVie (United States)), Dong Cheng(AbbVie (United States)), Jonathan A. Meulbroek(Abbott Fund), Suzanne M. Norvell(Atkins (United States)), Neal Goodwin(Champions Oncology (United States)), Hugh D. Falls(AbbVie (United States)), Erwin R. Boghaert(AbbVie (United States)), Michael J. Mitten(Abbott Fund), Kedar S. Vaidya(AbbVie (United States))
Cited by 185
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776